Kimberly Miller Miles, MD
Urogynecology and Reconstructive Pelvic Surgery · Webster, TXNPI 1003818394
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Astellas Pharma US Inc at 33.6% of the total. Reporting peaked in 2021 at $755 and has fallen 50.1% since, to $377 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in TX, where the typical reported total is $5,014.
Across 191 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$1K
- Sumitomo Pharma America, Inc.$669
- Pfizer$488
- 180 Medical, Inc.$200
- Laborie Medical Technologies Corp.$177
- Axonics, Inc.$176
- plus $782 from 14 others
What the payments were for
- Food & beverage$3,41291%
- Education$3128%
- Gifts$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 62 | $1,260 |
| Sumitomo Pharma America, Inc. | 39 | $669 |
| Pfizer | 28 | $488 |
| 180 Medical, Inc. | 10 | $200 |
| Laborie Medical Technologies Corp. | 9 | $177 |
| Axonics, Inc. | 7 | $176 |
| Urovant Sciences Inc | 7 | $138 |
| Convatec Inc. | 5 | $136 |
| Medtronic(2 entities) | 3 | $122 |
| Coloplast | 4 | $80 |
| Caldera Medical, Inc | 4 | $70 |
| Millicent US Inc | 3 | $61 |
| Therapeuticsmd, Inc. | 3 | $35 |
| Boston Scientific | 1 | $27 |
| Hollister Incorporated | 1 | $23 |
| Stryker | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Duchesnay USA Incorporated | 1 | $18 |
| Renovia Inc | 1 | $17 |
| Exact Sciences | 1 | $15 |
How this compares
$3,751 in reported general payments places this provider in the 40th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 200 | $187,963 |
| GemtesaVibegron | 182 | $167,160 |
| Mirabegron ErMirabegron | 70 | $57,827 |
| PremarinEstrogens, Conjugated | 121 | $51,100 |
| Solifenacin Succinate | 149 | $7,715 |
| Estradiol | 97 | $5,525 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 230 | $4,594 |
| Trospium Chloride ErTrospium Chloride | 24 | $4,337 |
| Cephalexin | 769 | $4,217 |
| Methenamine Hippurate | 31 | $3,805 |
| Fosfomycin Tromethamine | 24 | $3,686 |
| CefuroximeCefuroxime Axetil | 206 | $3,352 |
| Oxybutynin Chloride ErOxybutynin Chloride | 97 | $2,434 |
| Trimethoprim | 19 | $836 |
| Ciprofloxacin Hcl | 88 | $687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,260 | $187,963200 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $669 | $167,160182 claims |
| PfizerPremarin | $488 | $51,100121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
Other urogynecology and reconstructive pelvic surgery in Webster
- Stephen KrausSan Antonio$372K
- Keith XavierArlington$282K
- Tomas AntoniniAustin$183K
- Amanda WhiteAustin$108K
- Gazala SiddiquiHouston$81K
- Fiona LindoHouston$66K
- Peter LotzeHouston$48K
- Tracy Cannon-SmithArlington$29K
- Teresa IrwinSan Marcos$20K
- Oluwarotimi NetteyHouston$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.